Researchers at Massachusetts Eye and Ear/Harvard Medical School and Boston University have successfully shown neuroprotection in a Parkinson’s mouse model using new techniques to deliver drugs across the naturally impenetrable blood-brain barrier. Their findings, published in Neurosurgery, lend hope to patients around the world with neurological conditions that are difficult to treat due to a barrier mechanism that prevents approximately 98 percent of drugs from reaching the brain and central nervous system.
“We are developing a platform that may eventually be used to deliver a variety of drugs to the brain,” said senior author Benjamin S. Bleier, M.D. (in photo), of the department of otolaryngology at Mass. Eye and Ear/Harvard Medical School. “Although we are currently looking at neurodegenerative disease, there is potential for the technology to be expanded to psychiatric diseases, chronic pain, seizure disorders and many other conditions affecting the brain and nervous system down the road.”
Using nasal mucosal grafting, researchers delivered glial derived neurotrophic factor (GDNF), a therapeutic protein in testing for treating Parkinson’s disease, to the brains of mice. They showed through behavioral and histological data capture that their delivery method was equivalent to direct injection of GDNF – the current gold standard for delivering this drug in Parkinson’s disease despite its traumatic nature and high complication rates – in diffusing drugs to the brain.
The researchers chose to test their delivery method with GDNF because the therapy has been shown to delay and even reverse disease progression of Parkinson’s disease in pre-clinical models. The study was funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF).
“Brain diseases are notoriously difficult to treat due to the natural protections the body builds against intrusion,” said Jamie Eberling, Ph.D., senior associate director of MJFF research programs. “Dr. Bleier’s group has identified a potential avenue to pass that barrier, and we look forward to the next stage of research to further test its utility in people with Parkinson’s disease .”
Nasal mucosal grafting is a technique regularly used in the ENT field to reconstruct the barrier around the brain after surgery to the skull base. ENT surgeons commonly use endoscopic approaches to remove brain tumors through the nose by making a window through the blood-brain barrier to access the brain. Once they have finished the treatment, they use adjacent nasal lining to rebuild the hole in a permanent and safe way. The safety and efficacy of these methods have been well established through long-term clinical outcomes studies in the field, with the nasal lining protecting the brain from infection just as the blood brain barrier has done.
Dr. Bleier saw an opportunity to apply these techniques to the widespread clinical dilemma of delivering drugs across the barrier to the brain and central nervous system. By functionally replacing a section of the blood-brain barrier with nasal mucosa, which is more than 1,000 times more permeable than the native barrier, surgeons may create a “screen door” to allow for drug delivery to the brain and central nervous system.
The technique has the potential to benefit a large population of patients with neurodegenerative disorders, where there remains a specific unmet need for blood-brain penetrating therapeutic delivery strategies.
“We see this expanding beyond Parkinson’s disease, as there are multiple diseases of the brain that do not have good therapeutic options,” Dr. Bleier said. “It is a platform that opens doors for new discovery and could enable drug development for an underserved population.”
Read more:Â Researchers Develop Techniques to Bypass Blood-Brain Barrier, Deliver Drugs to Brain and Nervous System
The Latest on: neurodegenerative disorders
[google_news title=”” keyword=”neurodegenerative disorders” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: neurodegenerative disorders
- MD Anderson gets $20M gift to boost neurodegenerative researchon May 6, 2024 at 2:54 pm
The University of Texas MD Anderson Cancer Center in Houston has received a $20 million gift from a longtime donor that will go toward advancing research on Alzheimer's and other types of ...
- Team Hope Walk raises awareness for Huntington’s Diseaseon May 5, 2024 at 1:54 am
Saturday for the Team Hope Statewide Walk. The walk was to raise money for Huntington’s Disease. Huntington’s disease is a rare, neurodegenerative disease that causes nerve cells in the brain to ...
- Parkinson’s Disease: What to knowon May 5, 2024 at 12:00 am
Who hasn’t tapped fingers on a desk with anxiety or shook a leg under a table awaiting some sort of news? These motor impulses may seem involuntary, but they largely are under the control of the ...
- Creyon Bio, Cajal Neuroscience to Jointly Target Neurodegenerative Diseaseson May 3, 2024 at 7:37 am
By Daniella Parra Creyon Bio, Inc. and Cajal Neuroscience have teamed up to develop therapies for neurodegenerative diseases, they said. The companies aim to accelerate the development of treatments ...
- Leprosy drug may be effective in Huntington's disease, study suggestson May 3, 2024 at 6:16 am
A preclinical study from Karolinska Institutet offers hope for treating severe neurodegenerative diseases with an existing drug. The study suggests that the leprosy drug clofazimine may be effective ...
- Creyon Bio, Cajal Neuroscience partner to develop oligonucleotide-based medicines for neurodegenerative diseaseson May 3, 2024 at 4:30 am
Creyon Bio, Cajal Neuroscience partner to develop oligonucleotide-based medicines for neurodegenerative diseases: San Diego Friday, May 3, 2024, 17:00 Hrs [IST] Creyon Bio, Inc, a ...
- Why Coya Therapeutics Is A Smart Speculative Buy For Neurodegenerative Diseaseson May 1, 2024 at 3:45 am
Coya Therapeutics is a biotech company developing therapies for neurodegenerative diseases. Read why I deem COYA stock as a good speculative buy.
- UT Arlington student links worm behavior to brain diseaseon April 29, 2024 at 5:00 pm
UT Arlington undergraduate student turns her honor's thesis into a peer-reviewed publication on schizophrenia research.
- Alterity Therapeutics Presents New Data Demonstrating Potential of ATH434 to Treat Rare Neurodegenerative Disease Friedreich’s Ataxiaon April 29, 2024 at 4:54 am
New Evidence Indicates ATH434 can Function as an Iron Chaperone to Redistribute Iron –MELBOURNE, Australia and SAN FRANCISCO, April 29, ...
- Ley ELA: What is Spain's new neurodegenerative disorders law?on April 29, 2024 at 3:23 am
Spain's new 'ALS Law' has been expanded to include all other neurodegenerative disorders such as Alzheimer's, Parkinson's and Huntington's. Here's what you need to know.
via Bing News